Calliditas Therapeutics AB (publ)

LSE:0A5R Stock Report

Market Cap: SEK 11.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics Valuation

Is 0A5R undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A5R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 10.34k
Fair Value
98.0% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: 0A5R (SEK207) is trading below our estimate of fair value (SEK10342.07)

Significantly Below Fair Value: 0A5R is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A5R?

Key metric: As 0A5R is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0A5R. This is calculated by dividing 0A5R's market cap by their current revenue.
What is 0A5R's PS Ratio?
PS Ratio7x
SalesSEK 1.60b
Market CapSEK 11.24b

Price to Sales Ratio vs Peers

How does 0A5R's PS Ratio compare to its peers?

The above table shows the PS ratio for 0A5R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
INDV Indivior
1.3x1.6%UK£1.2b
HCM HUTCHMED (China)
4.3x16.7%UK£2.1b
APH Alliance Pharma
1.8x5.2%UK£330.3m
DPH Dechra Pharmaceuticals
5.8x7.9%UK£4.4b
0A5R Calliditas Therapeutics
7x32.5%SEK 11.2b

Price-To-Sales vs Peers: 0A5R is expensive based on its Price-To-Sales Ratio (7x) compared to the peer average (3.4x).

Price to Sales Ratio vs Industry

How does 0A5R's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x7.9%US$55.03m
No more companies available in this PS range
0A5R 7.0xIndustry Avg. 3.0xNo. of Companies6PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0A5R is expensive based on its Price-To-Sales Ratio (7x) compared to the European Pharmaceuticals industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is 0A5R's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A5R PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7x
Fair PS Ratio11.1x

Price-To-Sales vs Fair Ratio: 0A5R is good value based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (11.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A5R forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
SEK 227.50
0%
19.0%SEK 295.00SEK 177.00n/a4
Jan ’26n/a
SEK 227.50
0%
19.0%SEK 295.00SEK 177.00n/a4
Dec ’25n/a
SEK 227.50
0%
19.0%SEK 295.00SEK 177.00n/a4
Nov ’25n/a
SEK 227.50
0%
19.0%SEK 295.00SEK 177.00n/a4
Oct ’25SEK 206.80
SEK 227.50
+10.0%
19.0%SEK 295.00SEK 177.00n/a4
Sep ’25SEK 206.20
SEK 227.50
+10.3%
19.0%SEK 295.00SEK 177.00n/a4
Aug ’25SEK 206.20
SEK 221.25
+7.3%
15.3%SEK 270.00SEK 177.00n/a4
Jul ’25SEK 205.74
SEK 221.25
+7.5%
15.3%SEK 270.00SEK 177.00n/a4
Jun ’25SEK 208.13
SEK 208.00
-0.06%
21.4%SEK 270.00SEK 161.00n/a4
May ’25SEK 110.00
SEK 208.00
+89.1%
21.4%SEK 270.00SEK 161.00n/a4
Apr ’25SEK 113.44
SEK 208.00
+83.4%
21.4%SEK 270.00SEK 161.00n/a4
Mar ’25SEK 111.40
SEK 200.25
+79.8%
26.1%SEK 270.00SEK 140.00n/a4
Feb ’25SEK 112.20
SEK 202.75
+80.7%
27.5%SEK 280.00SEK 140.00n/a4
Jan ’25SEK 127.10
SEK 217.20
+70.9%
26.5%SEK 280.00SEK 140.00n/a5
Dec ’24SEK 92.50
SEK 217.20
+134.8%
26.5%SEK 280.00SEK 140.00n/a5
Nov ’24SEK 89.94
SEK 236.80
+163.3%
20.5%SEK 295.00SEK 154.00n/a5
Oct ’24SEK 97.89
SEK 236.80
+141.9%
20.5%SEK 295.00SEK 154.00SEK 206.805
Sep ’24SEK 91.55
SEK 237.40
+159.3%
20.0%SEK 295.00SEK 157.00SEK 206.205
Aug ’24SEK 103.70
SEK 246.40
+137.6%
23.0%SEK 310.00SEK 157.00SEK 206.205
Jul ’24SEK 86.70
SEK 246.40
+184.2%
23.0%SEK 310.00SEK 157.00SEK 205.745
Jun ’24SEK 93.45
SEK 246.40
+163.7%
23.0%SEK 310.00SEK 157.00SEK 208.135
May ’24SEK 123.29
SEK 259.80
+110.7%
20.0%SEK 315.00SEK 179.00SEK 110.005
Apr ’24SEK 125.30
SEK 259.80
+107.3%
20.0%SEK 315.00SEK 179.00SEK 113.445
Mar ’24SEK 101.30
SEK 255.80
+152.5%
23.7%SEK 315.00SEK 149.00SEK 111.405
Feb ’24SEK 97.60
SEK 246.80
+152.9%
26.2%SEK 305.00SEK 149.00SEK 112.205
Jan ’24SEK 92.45
SEK 236.00
+155.3%
28.8%SEK 305.00SEK 149.00SEK 127.104
Analyst Price Target
Consensus Narrative from 4 Analysts
SEK 226.41
Fair Value
8.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/11 00:55
End of Day Share Price 2024/10/11 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Calliditas Therapeutics AB (publ) is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ingird GafanhãoBryan Garnier & Co
Alexandru CogutBryan Garnier & Co
Erik HultgårdCarnegie Investment Bank AB